Vitamin D3 Crystallization Purity via Ethyl Acetate Hexane Solvent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current purification methods for vitamin D compounds, such as (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3, are inadequate as they often result in contamination with minor undesirable compounds, and existing methods like chromatographic purification are time-consuming and do not meet the required purity standards for therapeutic use.
Innovation Solution
A crystallization procedure using a solvent mixture of ethyl acetate and hexane, with specific ratios, to achieve crystalline form of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3, ensuring high purity and suitability for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatographic purification is used to purify vitamin D compounds, then purification efficiency is improved, but time consumption increases and the compound still does not meet required purity standards
Solution Approach 1:
The patent employs crystallization, a phase transition process, to purify vitamin D compounds. By controlling the phase change from dissolved state to crystalline state, the method achieves high purification efficiency while significantly reducing time consumption compared to chromatographic methods. The crystallization process naturally excludes impurities from the crystal lattice, achieving >99% purity without time-consuming column chromatography steps.
2Manufacturing precision
If multiple synthetic steps are used to prepare vitamin D compounds, then the desired product is obtained, but contamination with side-products from previous steps increases
Solution Approach 1:
The patent extracts the desired vitamin D compound from the complex mixture containing multiple impurities through selective crystallization. The crystallization process selectively precipitates the target compound while leaving side-products and contaminants in the mother liquor, effectively separating the desired product from harmful contaminants generated during multi-step synthesis.
Solution Approach 2:
The patent utilizes changes in physical parameters (temperature, solvent composition, saturation level) to control crystallization and achieve high purity. By carefully adjusting these parameters, the desired compound crystallizes in a pure form while impurities remain dissolved or form separate phases, effectively removing contamination from previous synthetic steps.
3Ease of manufacture
If commercial ergosterol material is used as starting material, then synthesis is simplified, but contamination with 1α-hydroxyvitamin D4 increases to about 1.5% by weight
Solution Approach 1:
The patent employs crystallization parameter optimization to reduce 1α-hydroxyvitamin D4 contamination from 1.5% to below 0.1-0.2%. By controlling temperature, solvent ratio, and crystallization rate, the process selectively crystallizes the desired vitamin D compound while excluding the D4 isomer, achieving high purity without complicating the synthesis route.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystallization process effectively purifies the vitamin D compound, achieving high purity and large crystal sizes suitable for X-ray diffraction analysis and pharmaceutical formulations, addressing the limitations of existing methods by providing a more efficient and effective purification technique.
Implementation Method 1
A crystallization procedure using a solvent mixture of ethyl acetate and hexane, with specific ratios, to achieve crystalline form of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3
Implementation Method 2
A crystallization procedure using a solvent mixture of ethyl acetate and hexane, with specific ratios
Data Source
AI summary
Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 from the solution.